US Stock Insider Trading | Medpace Holdings disclosed 1 insider transaction on February 17

K-LinePoet · 2026-02-20T06:04:44+00:00

On February 17, 2026, Medpace Holdings executive BURWIG SUSAN E purchased 11,000 shares on February 13 at a price of $107.93, totaling $1,185,500. Additionally, she has made multiple recent purchases of the company's stock, indicating confidence in the company's future.

K-LinePoet

2026-02-20 06:04:44

Abstract generation in progress

On February 17, 2026, Medpace Holdings (MEDP) disclosed an insider transaction. Executive BURWIG SUSAN E purchased 11,000 shares on February 13, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share (USD)	Total Amount (USD)
February 17, 2026	Executive	BURWIG SUSAN E	February 13, 2026	Buy	11,000	107.93	1,185,500
December 9, 2025	Executive	BURWIG SUSAN E	December 5, 2025	Buy	10,000	107.93	1,079,300
December 4, 2025	Executive	BURWIG SUSAN E	December 2, 2025	Buy	10,000	107.93	1,079,300
December 3, 2025	Shareholder with >10% stake	Troendle August J.	December 2, 2025	Sell	5,698	590.47	3,364,500
December 3, 2025	Shareholder with >10% stake	Troendle August J.	December 1, 2025	Sell	23,200	593.25	13,750,300
December 1, 2025	Shareholder with >10% stake	Troendle August J.	November 26, 2025	Sell	41,300	606.88	25,083,000
December 1, 2025	Shareholder with >10% stake	Troendle August J.	November 28, 2025	Sell	15,200	593.46	8,991,500
November 26, 2025	Shareholder with >10% stake	Troendle August J.	November 24, 2025	Sell	59,000	607.78	35,874,200
November 26, 2025	Shareholder with >10% stake	Troendle August J.	November 25, 2025	Sell	42,400	615.52	26,093,100
November 26, 2025	Executive	BURWIG SUSAN E	November 24, 2025	Sell	20,000	609.15	12,183,000

【Company Profile】

Medpace Holdings, Inc. was incorporated in Delaware on February 18, 2014. It is one of the world’s leading Contract Research Organizations (CROs), specializing in scientifically driven outsourced clinical development services for the biotech, pharmaceutical, and medical device industries. The company offers full-spectrum clinical development services from Phase I to Phase IV, with notable strengths in oncology, metabolic diseases, cardiology, antiviral and anti-infective (AVAI), and central nervous system (CNS) therapeutic areas. Medpace operates across all major therapeutic fields, leveraging its standardized operational model to provide timely, high-quality, and cost-effective clinical trial services to small and mid-sized biopharmaceutical companies, making it a preferred partner.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes